ArticleBMC complementary medicine and therapies2025
Inhibitory effect of [6]-shogaol against 3CLpro activity and SARS-CoV-2 infection.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Inhibitory effect of [6]-shogaol against 3CLpro activity and SARS-CoV-2 infection.BMC complementary medicine and therapies · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundZingiber officinale Roscoe (ginger) has been traditionally used not only as a culinary ingredient, but also for its medicinal properties. In Japan, ginger-derived crude drugs are categorized into dried ginger (Zingiberis Rhizoma [ZR]) or steamed ginger (Zingiberis Rhizoma processum [ZR-P]). Heating ginger converts gingerol, the primary component of ZR, into shogaol. In this study, we aimed to evaluate the inhibitory effects of ginger and its constituents on SARS-CoV-2 infection.
methodsWe assessed the inhibitory effects of ZR, ZR-P, [6]-gingerol, and [6]-shogaol on SARS-CoV-2 infection in VeroE6/TMPRSS2 cells. To understand the molecular mechanism underlying this inhibitory effect, we evaluated the activity of [6]-shogaol against the viral proteases 3 C-like protease (3CLpro) and papain-like protease (PLpro).
resultsWe observed that ZR-P (66.1% suppression at 50 µg/ml) and [6]-shogaol (70.0% suppression at 25 µM) exhibited significant inhibitory effects against SARS-CoV-2 infection. We found that [6]-shogaol effectively inhibited 3CLpro activities both in vitro (20.4% inhibition at 40 µM) and in FlipGFP reporter system (19.7% inhibition at 25 µM).
conclusionsThis study highlights [6]-shogaol and ZR-P as promising natural inhibitors of SARS-CoV-2, providing new insights into the pharmacological potential of traditional ginger preparations and their active components against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.